

**PARTICIPATION IN SMALLCAP EVENT
12 & 13 APRIL 2010 IN PARIS**

Nantes (France) – April 2, 2010 – VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat human diseases, will participate at the Smallcap Event to be held in Paris on April 12 and 13, 2010 for the third year in a row. This event will take place at Salons Hoche, 9 avenue Hoche 75008 Paris.

VIVALIS will present its technological and commercial advances for 2009, the financial results for the year published on April 6th, 2010, as well as its strategic outlook, including its recent purchase of Humalys.

VIVALIS' presence at this forum reflects its commitment to develop strong relations with its investors and increase its visibility within the financial community.

**Next financial press release:
6 April 2010, after NYSE Euronext market closing: 2009 annual results**

About the EB66[®] cell line

The EB66[®] cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth up to high cell densities in suspension in a serum-free medium (>40 millions cells/mL).

The BMF (Biologics Master File) for the registration of the EB66[®] cell line with the FDA (U.S. Food and Drug Administration) was filed on June 27, 2008.

The EB66[®] cells replicate a wide range of human and animal viruses and are currently used or being evaluated for the production of viral vaccines by the major players in vaccines.

The EB66[®] cells are easily genetically engineered to efficiently express recombinant proteins of interest (> 1 g/l). Monoclonal antibodies produced in EB66[®] cells have human-like glycosylation profile, with the remarkable additional feature of having reduced fucose content. This latter characteristic provides a better cytotoxic activity to antibodies, particularly useful in the treatment of cancer cells.

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines and monoclonal antibodies. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.

2. Through the Humalex® platform, VIVALIS proposes customers solutions for the generation, development and production of human antibodies. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,500 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next

Biotech indexes



Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr